

Priorities For The National Action Plan on Combating Antibiotic-Resistant Bacteria: 2020–2025

Presentation on the WG Report

Martin Blaser

Lonnie King

Mike Apley

Kathy Talkington

July 10, 2019

PACCARB

Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria

Working Group Members

- Council Members (voting and liaison)
- Interagency CARB Task Force Members
 - HHS: CDC, FDA, AHRQ, CMS, ASPR, ASPE, NIH, OGA
 - DoD, State, USAID, EPA
 - USDA: APHIS, ARS, FSIS

MARTY BLASER

Process

- Tasked by Secretary in September 2018 to identify 3-5 emerging areas within the five NAP goals
- RFI posted for public feedback, January Public meeting held with 31 panelists, then WG met to discuss feedback and distill recommendations to the Secretary
 - Council members developed the recommendations, the Task Force helped inform the process
- Identified 17 distinct recommendations across the five NAP goals


MARTY BLASER

RFI open from November 23, 2018 – January 7, 2019

180 responses from 67 respondents

Report Organization

- Figure in Executive Summary summarizes five major identified priorities (top)
 - Three additional priorities to incorporate across all five goals (bottom)
- Body of the report includes introduction and background, and then provides explanations for each recommendation with sub-bullets, by Goal.



LONNIE KING

Goal 1

SLOW THE EMERGENCE OF RESISTANT BACTERIA AND PREVENT THE SPREAD OF RESISTANT INFECTIONS

- Priority 1: Advance implementation of IP and AS programs through measurable, outcomes-based research.
- Priority 2: Widely implement IP and AS strategies that have been proven effective throughout healthcare settings and animal agriculture.
- Priority 3: Promote AS in companion animal health settings.
- Priority 4: Facilitate and support the adoption of new technologies and management practices that can reduce the need for antibiotic use in animal agriculture.
- Priority 5: Increase the use and interoperability of data systems to support AS.

MIKE APLEY

Goal 2

STRENGTHEN NATIONAL ONE HEALTH SURVEILLANCE EFFORTS TO COMBAT RESISTANCE

- Priority 1: Enhance antibiotic use and resistance reporting systems for human and animal health.
- Priority 2: Expand AMR reporting through NARMS and fund supporting research.
- Priority 3: Understand the role of antibiotics and resistance in the environment.

KATHY TALKINGTON

Goal 3

ADVANCE DEVELOPMENT AND USE OF RAPID AND INNOVATIVE DIAGNOSTIC TESTS FOR IDENTIFICATION AND CHARACTERIZATION OF RESISTANT BACTERIA

- Priority 1: Support studies that use clinical outcomes to evaluate the use of diagnostics and advance their integration into care.
- Priority 2: Develop incentives and reimbursement strategies to support uptake of diagnostics.
- Priority 3: Promote and support the development of new diagnostics and their integration into stewardship and AMR prevention programs in both human and animal health settings.

MIKE APLEY

Goal 4

ACCELERATE BASIC AND APPLIED RESEARCH AND DEVELOPMENT FOR NEW ANTIBIOTICS, OTHER THERAPEUTICS, AND VACCINES

- Priority 1: Adopt effective pull incentives for development of new antibiotics, vaccines, and alternatives.
- Priority 2: Continue to create push incentives for development of new antibiotics, vaccines, and alternatives.
- Priority 3: Advance research on optimal dose and duration of existing antibiotic therapies.
- Priority 4: Address shortages of existing antibiotics.

KATHY TALKINGTON

Goal 5

IMPROVE INTERNATIONAL COLLABORATION AND CAPACITIES FOR ANTIMICROBIAL PREVENTION, SURVEILLANCE, CONTROL, AND ANTIMICROBIAL RESEARCH AND DEVELOPMENT

- Priority 1: Enhance U.S. leadership in the global fight against AMR.
- Priority 2: Promote and support AMR activities in low- and middle- income countries.

MIKE APLEY

Additional Recommendations: Five Years and Beyond

- Integrate antibiotic resistance surveillance systems for One Health surveillance.
- Develop an integrated federal One Health research strategy.
- Develop a national, interagency effort to address antibiotic resistance issues around the globe.

LONNIE KING

Discussion and Vote